NASDAQ:REGNRegeneron Pharmaceuticals Stock Price, Forecast & News

Regeneron Pharmaceuticals' stock was trading at $464.70 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, REGN stock has increased by 38.0% and is now trading at $641.23. View which stocks have been most impacted by Coronavirus.

27 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 12 hold ratings, 14 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals will be holding an earnings conference call on Wednesday, August 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced its earnings results on Tuesday, May, 5th. The biopharmaceutical company reported $6.60 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.13 by $0.47. The biopharmaceutical company earned $1.83 billion during the quarter, compared to analyst estimates of $1.81 billion. Regeneron Pharmaceuticals had a net margin of 28.56% and a return on equity of 24.94%. The company's revenue was up 6.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $4.45 earnings per share. View Regeneron Pharmaceuticals' earnings history.

Regeneron Pharmaceuticals declared that its board has authorized a stock buyback program on Tuesday, November 5th 2019, which permits the company to repurchase $1,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to repurchase up to 2.9% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company's board of directors believes its stock is undervalued.

27 Wall Street analysts have issued twelve-month target prices for Regeneron Pharmaceuticals' stock. Their forecasts range from $325.00 to $750.00. On average, they anticipate Regeneron Pharmaceuticals' stock price to reach $573.26 in the next year. This suggests that the stock has a possible downside of 10.6%. View analysts' price targets for Regeneron Pharmaceuticals.

News stories about REGN stock have trended somewhat negative recently, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Regeneron Pharmaceuticals earned a daily sentiment score of -1.5 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 2,470,000 shares, an increase of 24.1% from the June 15th total of 1,990,000 shares. Based on an average trading volume of 1,430,000 shares, the days-to-cover ratio is presently 1.7 days. Approximately 2.3% of the company's shares are sold short. View Regeneron Pharmaceuticals' Current Options Chain.

Some companies that are related to Regeneron Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include Gilead Sciences (GILD), Netflix (NFLX), NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Biogen (BIIB), Micron Technology (MU), Walt Disney (DIS), Alphabet (GOOG) and Johnson & Johnson (JNJ).

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Regeneron Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include DNB Asset Management AS (0.07%), Envestnet Asset Management Inc. (0.06%), Hexavest Inc. (0.03%), State of Alaska Department of Revenue (0.03%), MERIAN GLOBAL INVESTORS UK Ltd (0.03%) and Veracity Capital LLC (0.01%). Company insiders that own Regeneron Pharmaceuticals stock include Andrew J Murphy, Arthur F Ryan, Bonnie L Bassler, Christopher R Fenimore, George L Sing, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry and Sanofi. View institutional ownership trends for Regeneron Pharmaceuticals.

REGN stock was sold by a variety of institutional investors in the last quarter, including Veracity Capital LLC, Jacobs & Co. CA, IFM Investors Pty Ltd, Carroll Financial Associates Inc., Nelson Van Denburg & Campbell Wealth Management Group LLC, HBW Advisory Services LLC, and Stonebridge Capital Management Inc.. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Andrew J Murphy, Arthur F Ryan, Bonnie L Bassler, Christopher R Fenimore, George L Sing, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry, and Sanofi. View insider buying and selling activity for Regeneron Pharmaceuticals.

REGN stock was bought by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd, State of Alaska Department of Revenue, DNB Asset Management AS, Envestnet Asset Management Inc., Patton Fund Management Inc., Canandaigua National Corp, Engrave Wealth Partners LLC, and Minot Wealth Management LLC. View insider buying and selling activity for Regeneron Pharmaceuticals.

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of REGN stock can currently be purchased for approximately $641.23.

Regeneron Pharmaceuticals has a market capitalization of $70.55 billion and generates $7.86 billion in revenue each year. The biopharmaceutical company earns $2.12 billion in net income (profit) each year or $21.47 on an earnings per share basis. Regeneron Pharmaceuticals employs 8,100 workers across the globe.

The official website for Regeneron Pharmaceuticals is www.regeneron.com.

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]